Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avapritinib in Chinese patients with advanced GIST
NCT04254939Phase 2Completed
- Sponsor
- CStone Pharmaceuticals
- Start
- Aug 2019
- Primary completion
- Apr 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avapritinib in gastrointestinal stromal tumor (GIST), sponsored by CStone Pharmaceuticals. Primary endpoints: Recommended Phase II dose, Incidence of Dose Limiting Toxicities and 3 more. Started Aug 2019; status: completed.
02
Drugs
avapritinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT04254939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04254939.